Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machine‐learning assisted morphometrics. Issue 5 (7th December 2020)

• Record Type: Journal Article
• Authors: Rosenberg, Carina A.; Bill, Marie; Rodrigues, Matthew A.; Hauerslev, Mathias; Kerndrup, Gitte B.; Hokland, Peter; Ludvigsen, Maja
• Is Part Of: Cytometry. Volume 100:Issue 5(2021)
• Page Start: 554
• Page End: 567
• Publication Date: 2020-12-07
• Subjects: dyserythropoiesis -- high‐throughput morphometric quantification -- imaging flow cytometry -- myelodysplastic syndrome; Flow cytometry -- Diagnostic use -- Periodicals; Cytodiagnosis -- Periodicals; 616.07582
• DOI: 10.1002/cyto.b.21975
• Languages: English
• ISSNs: 1552-4949

Abstract

Abstract: Background: The hallmark of myelodysplastic syndrome (MDS) remains dysplasia in the bone marrow (BM). However, diagnosing MDS may be challenging and subject to inter‐observer variability. Thus, there is an unmet need for novel objective, standardized and reproducible methods for evaluating dysplasia. Imaging flow cytometry (IFC) offers combined analyses of phenotypic and image‐based morphometric parameters, for example, cell size and nuclearity. Hence, we hypothesized IFC to be a useful tool in MDS diagnostics. Methods: Using a different‐from‐normal approach, we investigated dyserythropoiesis by quantifying morphometric features in a median of 5953 erythroblasts (range: 489–68, 503) from 14 MDS patients, 11 healthy donors, 6 non‐MDS controls with increased erythropoiesis, and 6 patients with cytopenia. Results: First, we morphometrically confirmed normal erythroid maturation, as immunophenotypically defined erythroid precursors could be sequenced by significantly decreasing cell‐, nuclear‐ and cytoplasm area. In MDS samples, we demonstrated cell size enlargement and increased fractions of macronormoblasts in late‐stage erythroblasts (both p < .0001). Interestingly, cytopenic controls with high‐risk mutational patterns displayed highly aberrant cell size morphometrics. Furthermore, assisted by machine learning algorithms, we reliably identified and enumerated true binucleated erythroblasts at a significantly higher frequency in two out of three erythroblast maturation stages in MDS patients compared to normal BM (both p = .0001). Conclusion: We demonstrate proof‐of‐concept results of the applicability of automated IFC‐based techniques to study and quantify morphometric changes in dyserythropoietic BM cells. We propose that IFC holds great promise as a powerful and objective tool in the complex setting of MDS diagnostics with the potential for minimizing inter‐observer variability.